New research published today in Nature from Ryan Flynn, MD, PhD, in collaboration with Vijay Rathinam, DVM, PhD, and his graduate student Vincent Graziano at UConn Health and other colleagues at Boston Children’s Hospital and UConn Health has uncovered powerful evidence that may explain why a new chemical modification of RNA is made in cells. The findings could provide new concepts for understanding the development of autoimmunity and how bacterial pathogens are detected — and ultimately help identify new therapeutic targets.

A new report from the Gerontological Society of America provides critical guidance for health care providers working with the nation’s growing older adult population, highlighting strategies to improve communication, build trust, and support better health outcomes.

 (WASHINGTON – August 4, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The findings suggest that underuse of these drugs may help explain why MDS outcomes have not improved over the past two decades since these life-extending medications became available.